Discontinued drugs in 2005: endocrine and metabolic.
This perspective describes the compounds from the endocrine and metabolic area that were discontinued during the calendar year 2005. This is a continuation of a series of perspectives of each of the editorial areas summarized by Expert Opinion on Investigational Drugs. The candidates for this summary were being developed in the areas of treatment of diabetes and diabetes complications, as well as reproductive and urogenital health issues.
Colca
Jerry R
JR
Kalamazoo Metabolic Research, 125 South Kalamazoo, Mall number 604, Kalamazoo, MI 49007, USA. jerry.colca@kalmetres.com
D000818:Animals; D048909:Diabetes Complications / Q000188:drug therapy; D064420:Drug-Related Side Effects and Adverse Reactions; D004700:Endocrine System Diseases / Q000188:drug therapy*; D012739:Gonadal Steroid Hormones / Q000009:adverse effects / Q000737:chemistry; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000737:chemistry; D008659:Metabolic Diseases / Q000188:drug therapy*
D012739:Gonadal Steroid Hormones; D007004:Hypoglycemic Agents